Drug development services
-
Automating chemical drug discovery and synthesis
SRI International’s continuous flow SynFini™ Suite produced multiple nucleoside antivirals in a single day.
-
Partnering to Rapidly Advance ZMappTM for Ebola Treatment
SRI scientists partner with Mapp Biopharmaceutical to accelerate FDA approval for clinical trials.
-
HOPO: Partnering to Advance Therapy for Radiation Exposure
SRI scientists collaborate with Lawrence Berkeley National Laboratory to chart a path for obtaining regulatory approval for a clinical development plan for a novel decorporation agent.
-
SRI awarded $107 million NIAID-DAIDS contract to provide preclinical services for HIV therapeutics
SRI International has been awarded a contract from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases and the Division of AIDS to support research and product development for human immunodeficiency virus (HIV), Mycobacterium tuberculosis (MTB) complex, and hepatitis B and C viruses (HBV/HCV).
-
SRI International awarded $40 million NICHD contract for pre-clinical development of new male and female contraceptive products
SRI International has been awarded a Biological Testing Facility contract to complete discovery and preclinical development of new contraceptive compounds.
-
SRI receives NSF grant to create new viral classification system
SRI International has been awarded a National Science Foundation (NSF) grant through the Grants for Rapid Response (RAPID) program. RAPID is a mechanism used by the NSF to provide funds for urgent research that addresses unexpected disasters or events such as the COVID-19 pandemic. SRI scientists will use the RAPID grant to develop a first-of-its-kind…